Simbec-Orion to conduct a Phase II clinical trial in pulmonary sarcoidosis patients for Molecure’s OATD-01
18/07/2023
Warsaw, 3rd July 2023 Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program. Read the full press release here
Welcome to Simon Jennings
05/07/2023
We are delighted to share that Simon Jennings as joined Simbec-Orion as Vice President, Data Sciences. Simon has over 35 years in the pharmaceutical and CRO industry comprising a variety of global leadership roles in Biostatistics, Data Management, Statistical Programming and Biometrics Project Management covering all phases of clinical research in Glaxo, Celltech, Eisai, Sandoz/Novartis […]
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement
27/06/2023
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement ‹‹CIR – Crédit d’Impôt Recherche›› qui donne droit aux entreprises françaises qui sont assujetties à l’impôt sur les sociétés en France, la capacité de réclamer un allégement fiscal sur les coûts générés pour des activités concernant la Recherche & Développement externalisée par le […]
Steering Your Path to the Clinic, Complimentary Breakfast Workshop, June 29, Oxford UK
07/06/2023
How confident are you in your route to the clinic? There are multiple hurdles to be navigated, many of which can knock your development programme off course and threaten that all-important milestone. Optimising your clinical study design, so that it delivers the endpoints you need, without wasting time and budget, is crucial to keeping your […]
First Dose Administered in Phase I Trial of Novel Treatment for Cognitive Impairment Associated with Schizophrenia
09/03/2023
February 27, 2023 Simbec-Orion are pleased to share that dosing with MDI-26478, Cardiff University’s Medicines Discovery Institute’s (MDI) potential novel treatment for cognitive impairment associated with schizophrenia and a range of disorders connected with the brain and central nervous system, has commenced in our MHRA Accredited Phase I Unit in South Wales. This is an […]
Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
09/01/2023
The successful delivery of another Phase I clinical trial by the team at Simbec-Orion has resulted in the achievement of a significant milestone for Mission Therapeutics. MTX652 was shown to be well tolerated and safe up to a single dose of 200mg and multiple doses of 100mg once daily for 14 days. We share the […]
Sustained clinical response in a patient with metastatic breast cancer treated with MP0274
17/11/2022
Today we celebrate the success of our colleague, and Scientific Advisory Board member, Dr Samson Fung. Dr Fung was recently co-authored in a publication by JCO Precision Oncology released on 4th November, 2022, for his work as a study director in a Ph I FIH clinical study in patients with metastatic breast cancer. Believed to […]